心血管疾病已经成为我国城乡居民的首要死亡原因，给人民和社会的带来的经济负担日益加重。其中，心力衰竭作为诸多心血管疾病的终末阶段，是二十一世纪最重要的心血管病之一，其死亡率和癌症相当，是严重影响人民健康的重要公共卫生问题。近年来，心血管病学领域取得了巨大进展。基础医学及相关学科的发展，进一步丰富了对心血管疾病发病和病理生理机制的认识。心力衰竭领域的进展一日千里，有鉴于此，我们亟需一本能反映此领域近期新循证医学进展的专著，以供广大心血管专科医师参考。本书围绕慢性心力衰竭这个主题，重点关注慢性心衰的临床诊疗及管理，介绍慢性心力衰竭的流行病学、病理生理机制近期新药物和非药物治疗进展、康复及管理理念，并结合心衰不同病因及合并疾病情况进行介绍，尽可能的反映出近年来慢性心衰领域的前沿诊疗措施和技术。

心血管疾病已经成为我国城乡居民的首要死亡原因，给人民和社会的带来的经济负担日益加重。其中，心力衰竭作为诸多心血管疾病的终末阶段，是二十一世纪最重要的心血管病之一，其死亡率和癌症相当，是严重影响人民健康的重要公共卫生问题。近年来，心血管病学领域取得了巨大进展。基础医学及相关学科的发展，进一步丰富了对心血管疾病发病和病理生理机制的认识。心力衰竭领域的进展一日千里，有鉴于此，我们亟需一本能反映此领域近期新循证医学进展的专著，以供广大心血管专科医师参考。本书围绕慢性心力衰竭这个主题，重点关注慢性心衰的临床诊疗及管理，介绍慢性心力衰竭的流行病学、病理生理机制近期新药物和非药物治疗进展、康复及管理理念，并结合心衰不同病因及合并疾病情况进行介绍，尽可能的反映出近年来慢性心衰领域的前沿诊疗措施和技术。

"第一章  慢性心力衰竭的流行病学 ······················································································· 1
第二章  慢性心力衰竭的病理生理机制 ················································································ 10
第三章  慢性心力衰竭的诊断和评估 ··················································································· 17
第一节  慢性心力衰竭诊断概述 ··················································································· 17
第二节  超声心动图诊断 ···························································································· 21
第三节  放射学诊断 ·································································································· 31
第四节  慢性心力衰竭的评估 ······················································································ 56
第四章  慢性心力衰竭的药物治疗 ······················································································ 86
第一节  血管紧张素转换酶（受体、受体脑啡肽酶）抑制剂 ··············································· 86
第二节  β受体阻滞剂 ······························································································ 105
第三节  钠.-葡萄糖耦联转运体 2抑制剂 ······································································ 121
第四节  盐皮质激素受体拮抗剂 ················································································· 130
第五节  正性肌力药物 ····························································································· 146
第六节  利尿剂······································································································· 158
第七节  药物方案的调整及优化 ················································································· 162
第五章  慢性心力衰竭的非药物治疗 ················································································· 168
第一节  连续性肾脏替代治疗 ···················································································· 168
第二节  起搏治疗 ··································································································· 179
第三节  心脏收缩力调节器 ······················································································· 197
第四节  主动脉内球囊反搏 ······················································································· 205
第五节  体外膜肺氧合 ······························································································211
第六节  微轴向心室辅助装置（以 Impella为例） ··························································· 219
第七节  颈动脉窦刺激及交感节神经消融 ····································································· 230
第八节  二尖瓣外科成形术及介入技术 ········································································ 238
第九节  左心室减容术 ····························································································· 249
第十节  心室辅助装置 ····························································································· 257
第十一节  心脏移植 ································································································ 265
第六章  慢性心力衰竭合并其他疾病 ················································································· 276
第一节  高血压······································································································· 276
第二节  冠心病······································································································· 284
第三节  心房颤动 ··································································································· 293
第四节  糖尿病······································································································· 316
第五节  肥厚型心肌病 ····························································································· 330
第六节  扩张型心肌病 ····························································································· 340
第七节  心脏淀粉样变性 ·························································································· 360
第八节  炎症性心肌病 ····························································································· 366
第九节  心肾综合征 ································································································ 376
第十节  呼吸系统疾病 ····························································································· 387
第十一节  甲状腺疾病 ····························································································· 404
第十二节  肺动脉高压 ····························································································· 413
第十三节  瓣膜性心脏病 ·························································································· 431
第十四节  抗肿瘤治疗相关心力衰竭 ··········································································· 443
第十五节  结缔组织疾病 ·························································································· 455
第七章  慢性心力衰竭的康复治疗 ···················································································· 463
第一节  体力活动的益处和风险 ················································································· 463
第二节  运动前筛查及评估 ······················································································· 464
第三节  运动测试和结果分析 ···················································································· 469
第四节  运动处方 ··································································································· 472
第五节  促进主动运动的策略 ···················································································· 475
第八章  慢性心力衰竭的全程管理 ···················································································· 483
第九章  干细胞治疗在心力衰竭中的应用 ··········································································· 491
附录  心力衰竭相关的重要临床研究 ················································································· 498 "